FIELD: medicine.
SUBSTANCE: invention relates to a peroral or injectable pharmaceutical composition suitable for treatment of human immunodeficiency virus (HIV) usage, comprising a therapeutically effective amount of at least one antiretroviral drug, which contains reverse transcriptase inhibitor based on nucleotide analog (NRTI) selected from a group including: tenofovir alafenamide fumarate, tenofovir disoproxil fumarate, adefovir and a combination thereof; or (ii) protease inhibitor (PI) containing darunavir and a therapeutically effective amount of at least one activator or pharmacokinetics improver which contains piperine, tetrahydropiperine, cis-piperine, trans-piperine, cis,trans-piperine, trans,cis-piperine, cis,cis-piperine, trans,trans-piperine, or a combination thereof. Present invention also relates to a producing method of a peroral or injectable pharmaceutical composition, to a treatment kit for human immunodeficiency virus (HIV), to the usage of a combination for increasing the bioavailability of an oral antiretroviral drug, to a peroral or injectable pharmaceutical composition suitable for hepatitis B viruses treatment, to a treatment kit for hepatitis B viruses.
EFFECT: bioavailability of antiretroviral drugs enhancement.
21 cl, 14 ex, 31 tbl, 8 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION, ITS APPLICATION AND METHODS FOR TREATMENT USING SPECIFIED COMBINATION | 2018 |
|
RU2755710C2 |
| ANELLATED 9-HYDROXY-1,8-DIOXO-1,3,4,8-TETRAHYDRO-2H-PYRIDO[1,2-A]PYRAZINE-7-CARBOXAMIDES - INTEGRASE INHIBITORS, METHODS FOR PREPARING AND USING THEREOF | 2019 |
|
RU2717101C1 |
| NOVEL QUINOLINE DERIVATIVE FOR USE IN TREATING AND PREVENTING VIRAL INFECTIONS | 2016 |
|
RU2723013C2 |
| CYCLOBUTYL (S)-2-[[[R)-2-(6-AMINOPURIN-9-YL)-1-METHYL-ETOXY]METHYL-PHENOXY-PHOSPHORYL]AMINO]-PROPANOATES, METHOD OF THEIR PRODUCTION AND APPLICATION | 2017 |
|
RU2647576C1 |
| ANTIRETROVIRAL COMBINATION | 2008 |
|
RU2531089C2 |
| ANTI-RETROVIRAL COMBINATION | 2014 |
|
RU2675831C2 |
| QUINOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING VIRAL INFECTION | 2016 |
|
RU2723016C2 |
| COMBINED DRUG FOR VIRAL INFECTION THERAPY | 2017 |
|
RU2662160C9 |
| PHARMACEUTICAL ANTIRETROVIRAL COMPOSITION | 2013 |
|
RU2648457C2 |
| NUCLEOTIDES INCLUDING N-[(S)-1-CYCLOBUTOXYCARBONYL]PHOSPHORAMIDATE FRAGMENT, THEIR ANALOGS AND THEIR APPLICATION | 2017 |
|
RU2659388C1 |
